Dual-Photosensitizer Nanoplatform Based on Near-Infrared Excitation Orthogonal Emission Nanomaterials for Enhanced Photodynamic Therapy of Tumors

ACS Appl Bio Mater. 2023 Jun 19;6(6):2394-2403. doi: 10.1021/acsabm.3c00212. Epub 2023 May 22.

Abstract

Photodynamic therapy (PDT) is considered as a promising therapeutic approach for clinical cancer treatment. However, the hypoxia of the tumor microenvironment leads to the low effect of single PDT. Here, a dual-photosensitizer nanoplatform based on near-infrared excitation orthogonal emission nanomaterials is constructed by introducing two kinds of photosensitizers into the nanosystem. Orthogonal emission upconversion nanoparticles (OE-UCNPs) were used as light conversion reagents to generate red emission under 980 nm irradiation and green emission under 808 nm irradiation. On the one hand, merocyanine 540 (MC540) is introduced as a photosensitizer (PS), which can absorb green light to generate reactive oxygen species (ROS) and trigger PDT for tumor treatment. On the other hand, another photosensitizer, chlorophyll a (Chla), which can be excited by red light, has also been introduced into the system to build a dual PDT nanotherapeutic platform. The introduction of photosensitizer Chla can synergistically increase ROS concentration to accelerate cancer cell apoptosis. Our research shows that this dual PDT nanotherapeutic platform combined with Chla has better therapeutic effects and effectively destroys cancer.

Keywords: cancer treatment; chlorophyll a; near-infrared; photodynamic therapy; photosensitizer; upconversion nanoparticle.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chlorophyll A
  • Humans
  • Nanoparticles*
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Photochemotherapy*
  • Photosensitizing Agents / pharmacology
  • Photosensitizing Agents / therapeutic use
  • Reactive Oxygen Species
  • Tumor Microenvironment

Substances

  • Photosensitizing Agents
  • Reactive Oxygen Species
  • Chlorophyll A